Waypoint Capital Advisors LLC Grows Holdings in Pfizer Inc. (NYSE:PFE)

Waypoint Capital Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the third quarter, HoldingsChannel reports. The fund owned 8,980 shares of the biopharmaceutical company’s stock after acquiring an additional 468 shares during the period. Waypoint Capital Advisors LLC’s holdings in Pfizer were worth $260,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PFE. Chicago Capital LLC boosted its position in shares of Pfizer by 0.9% in the 3rd quarter. Chicago Capital LLC now owns 75,895 shares of the biopharmaceutical company’s stock worth $2,196,000 after purchasing an additional 698 shares in the last quarter. Everett Harris & Co. CA raised its stake in Pfizer by 21.7% during the third quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock valued at $6,319,000 after buying an additional 38,870 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its stake in shares of Pfizer by 16.9% in the third quarter. Key Client Fiduciary Advisors LLC now owns 28,710 shares of the biopharmaceutical company’s stock worth $831,000 after acquiring an additional 4,156 shares during the last quarter. Bonness Enterprises Inc. increased its holdings in shares of Pfizer by 3.7% during the third quarter. Bonness Enterprises Inc. now owns 156,208 shares of the biopharmaceutical company’s stock valued at $4,521,000 after acquiring an additional 5,600 shares in the last quarter. Finally, TriaGen Wealth Management LLC purchased a new position in shares of Pfizer in the 3rd quarter worth about $202,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Trading Down 0.2 %

Shares of NYSE:PFE opened at $29.22 on Friday. The stock’s 50-day simple moving average is $29.07 and its two-hundred day simple moving average is $28.44. The stock has a market capitalization of $165.58 billion, a price-to-earnings ratio of -487.00, a PEG ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.